KKR Genetic Disorder L.P. - 12 May 2025 SCHEDULE 13D/A Report for BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share (BBIO)

Filing Manager
KKR Genetic Disorder L.P.
Reporting Manager
KKR Genetic Disorder L.P.
Security
BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share
Symbol
BBIO
Shares outstanding
189,442,443 shares
Disclosed Ownership
13,260,971 shares
Ownership
7%
Form type
SCHEDULE 13D/A
Filing time
14 May 2025, 17:52:58 UTC
Date of event
12 May 2025
Previous filing
07 Mar 2025
SEC
View on sec.gov

Reporting Managers (9)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
KKR Genetic Disorder L.P. 7% 13,260,971 13,260,971 0 /s/ Christopher Lee Christopher Lee, Assistant Secretary, KKR Genetic Disorder GP LLC, its general partner 0001780408
KKR Genetic Disorder GP LLC 7% 13,260,971 13,260,971 0 /s/ Christopher Lee Christopher Lee, Assistant Secretary
KKR Group Partnership L.P. 7% 13,260,971 13,260,971 0 /s/ Christopher Lee Christopher Lee, Secretary, KKR Group Holdings Corp., its general partner
KKR Group Holdings Corp. 7% 13,260,971 13,260,971 0 /s/ Christopher Lee Christopher Lee, Secretary
KKR Group Co. Inc. 7% 13,260,971 13,260,971 0 /s/ Christopher Lee Christopher Lee, Secretary
KKR & Co. Inc. 7% 13,260,971 13,260,971 0 /s/ Christopher Lee Christopher Lee, Secretary
KKR Management LLP 7% 13,260,971 13,260,971 0 /s/ Christopher Lee Christopher Lee, Assistant Secretary
Henry R. Kravis 7% 13,260,971 0 13,260,971 /s/ Christopher Lee Christopher Lee, Attorney-in-fact
George R. Roberts 7% 13,260,971 0 13,260,971 /s/ Christopher Lee Christopher Lee, Attorney-in-fact